TP53 and mismatch repair cancer syndrome 1: IHC enables the detection of abnormal p53 expression and mismatch repair deficiency, while PCR (polymerase chain reaction) and sequencing methods are used to identify pathogenic POLE mutations and the presence of MSI [16,17].